Years of Experience in Life Sciences Investment Management
Adds Depth to Board
QUEBEC CITY, March 22
/PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX: AEZ) (the "Company"), a late-stage drug development
company specialized in oncology and endocrinology, is pleased to
announce the appointment of Michael
Meyers, MPH, to its Board of Directors.
Mr. Meyers is a co-founding member, Chief Executive Officer and
Chief Investment Officer of Arcoda Capital Management LP, managing
the Arcoda Global Healthcare Funds, long-short funds investing
primarily in publicly traded equity securities of healthcare
companies across a range of healthcare sub-sectors. Prior to
founding Arcoda in 2007, Mr. Meyers was a Partner and Portfolio
Manager of GoldenTree Asset Management LP. Between 2002 and 2006,
he was a founding Managing Partner, Portfolio Manager and Sector
Head of Healthcare of a long-short money management firm in
New York.
Between 2000 and 2003, Mr. Meyers was a Managing Director,
Partner and Director of a life sciences venture capital firm
located in New York and
Zurich, Switzerland. Between 1997
and 2000, he was Director, Biotechnology and Pharmaceutical
Investment Banking at Merrill Lynch & Co. Between 1993 and
1997, Mr. Meyers was Vice President, Health Care Investment Banking
at Cowen & Company. He held earlier positions at
St. Barnabas Hospital system, and Hambrecht & Quist in
New York. Mr. Meyers holds a
Masters in Public Health, in Health Policy and Management, from
Columbia University and an A.B. in
Biology from Brandeis University.
Juergen Engel, Ph.D., President
and CEO of Aeterna Zentaris stated, "Michael Meyers brings a tremendous amount of
experience to Aeterna Zentaris, and we are very pleased to have him
serve on our Board. His track record of investment management in
the life sciences sector is extraordinary, and will be of great
assistance to us as we focus on bringing our late-stage oncology
compounds closer to market."
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development
company currently investigating potential treatments for various
cancers including colorectal, ovarian, endometrial cancer and
multiple myeloma. The Company's innovative approach of
"personalized medicine" means tailoring treatments to a patient's
specific condition and to unmet medical needs. Aeterna Zentaris'
deep pipeline is drawn from its proprietary discovery unit
providing the Company with constant and long-term access to
state-of-the-art therapeutic options. For more information please
visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbour provisions of the U.S. Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties that could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects, the successful and timely completion of clinical
studies, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related
to the regulatory process and general changes in economic
conditions. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
forward-looking statements. Investors are cautioned not to rely on
these forward-looking statements. The Company does not undertake to
update these forward-looking statements. We disclaim any obligation
to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained
herein to reflect future results, events or developments, unless
required to do so by a governmental authority or by applicable
law.
SOURCE AETERNA ZENTARIS INC.